New Trends in Cutaneous Melanoma Surgery

  • Jacopo Scala G. Marconi University, Rome, Italy
  • Aleksandra Vojvodic Department of Dermatology and Venereology, Military Medical Academy, Belgrade, Serbia
  • Petar Vojvodic Clinic for Psychiatric Disorders “Dr. Laza Lazarevic”, Belgrade, Serbia
  • Tatjana Vlaskovic-Jovicevic Clinic for Psychiatric Disorders “Dr. Laza Lazarevic”, Belgrade, Serbia
  • Zorica Peric-Hajzler Military Medical Academy, Belgrade, Serbia
  • Dusica Matovic Military Medical Academy, Belgrade, Serbia
  • Sanja Dimitrijevic Department of Gynecology, Military Medical Academy, Belgrade, Serbia
  • Jovana Vojvodic Clinic for Psychiatric Disorders “Dr. Laza Lazarevic”, Belgrade, Serbia
  • Goran Sijan Clinic for Plastic Surgery and Burns, Military Medical Academy, Belgrade, Serbia
  • Nenad Stepic Chief of Clinic for Plastic Surgery and Burns, Military Medical Academy, Belgrade, Serbia
  • Uwe Wollina Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Dresden, Germany
  • Michael Tirant G. Marconi University, Rome, Italy
  • Van Thuong Nguyen Vietnam National Hospital of Dermatology and Venereology, Hanoi, Vietnam
  • Massimo Fioranelli Department of Nuclear Physics, sub-nuclear and radiation, G. Marconi University, Rome, Italy
  • Torello Lotti University of Rome G. Marconi, Rome, Italia
Keywords: cutaneous, melanoma, surgery


The main surgical treatment for melanoma consists in wide surgical excision of the primary lesion and the sentinel node but in recent times management of melanoma is rapidly evolving with the introduction of new systemic therapies, like BRAF inhibitors, MEK inhibitors and antibodies anti-PD-1 that show good results in controlling even advanced stages of the disease. This review aims to present data for the optimal surgical management of patients with malignant melanoma.


Download data is not yet available.


Metrics Loading ...

Plum Analytics Artifact Widget Block

Author Biography

Torello Lotti, University of Rome G. Marconi, Rome, Italia

Prof. Lotti is Full Professor of the Dermatology and Venereology at University of Studies Guglielmo Marconi, Rome, Italy. He is Honorary Professor of Dermatology - China Medical University Shenyang (2011), Lecturer at the New York Academy of Sciences "Howard Fox Memorial Lecture" (14 March 2012 - New York, NY – USA), and Chair, Executive Scientific Committee Vitiligo Research Foundation, New York , NY , USA. He is President of the World Health Academy, Dermatology since 2013. He has been Full Professor of the Dermatology and Venereology Division at University of Florence School of Medicine, Florence, Italy, from 2006 to 2010. He is Visiting Professor in six International Universities worldwide, and Key Note Lecturer in several international dermatology Societies. His activities in serving Dermatology have been numerous: President of the Italian Society of Dermatology and Venereology (SIDeMaST , 2009-2010) and President of the International Society of Dermatology ( ISD, 2009-2010), President of the European Society for Cosmetic and Aesthetic Dermatology (2003-2004), Editor in Chief of the Journal of the European Academy of Dermatology and Venereology (1992-2002) , Editor "Therapeutic Hotline"- Dermatologic Therapy (2007-)and served as Editor in Chief of the Giornale Italiano di Dermatologia in the period of presidency of the Societa' Italiana di Dermatologia (2009-2010). He has been President of numerous international congresses and is currently Editor in Chief of the Giornale Italiano di Dermatologia e Venereologia ( 2010-2020 ). He is Ordinary Member of the main Scientific Societies worldwide (EADV, SIDEV , ESDR , ISD, AAD, SID) and Honorary Member of several Scientific Societies of the Dermatology field. Moreover, he is a Scientific reviewer of ten sectorial journals, among which are the British Journal of Dermatology, Journal of Investigative Dermatology, Journal of the American Academy of Dermatology , Dermatologic Therapy. He has authored 1054 scientific publications (393 peer reviewed articles, 288 books chapters e 365 abstracts). For more information, see


Wasif N, Bagaria SP, Ray P, Morton DL. Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol. 2011; 104(2):111-115. PMid:21381040 PMCid:PMC3199373

Tchernev G, Chokoeva AA, Wollina U, Lotti T. De novo congenital malignant melanoma: whats new in diagnosis and treatment? Dermatol Ther. 2016; 29(1):13-4. PMid:26279460

França K, Lotti T. Stress coping strategies for the optimal treatment of melanoma. Dermatol Ther. 2017; 30(1). PMid:27592687

Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970; 172(5): 902-8. PMid:5477666 PMCid:PMC1397358

Kunishige JH, Brodland DG, Zitelli JA. Margins for standard excision of melanoma in situ. J Am Acad Dermatol. 2013; 69(1):164. PMid:23768291

Sober AJ. Diagnosis and management of early melanoma: a con- sensus view. Semin Surg Oncol. 1993; 9(3):194-7.

Managing melanoma. National Institute for Health and Care Excellence, 2018.

Malignt Melanom. Swedish National Treament Guidelines. Regional Cancer Centrum, 2017.

Work G, Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2018.

Sladden MJ, Balch C, Barzilai DA, Berg DA, Freiman A, Handiside T, et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev. 2009; (4):CD004835. PMid:19821334

Wheatley K, Wilson JS, Gaunt P, Marsden JR. Surgical excision margins in primary cutaneous melanoma: a meta-analysis and Bayesian probability evaluation. Cancer Treat Rev. 2016; 42:73- 81. PMid:26563920

Balch CM, Soong SJ, Smith T, Ross MI, Urist MM, Karakousis CP, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol. 2001; 8(2):101-8. PMid:11258773

Hayes AJ, Maynard L, Coombes G, Newton-Bishop J, Timmons M, Cook M, et al. Wide versus narrow excision margins for high- risk, primary cutaneous melanomas: long-term follow-up of surviv- al in a randomized trial. Lancet Oncol. 2016; 17(2):184-92.

Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014; 370(7):599-609. PMid:24521106 PMCid:PMC4058881

Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017; 376(23):2211-22. PMid:28591523 PMCid:PMC5548388

Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, German Dermatologic Cooperative Oncology Group (DeCOG), et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multi-centre, randomised, phase 3 trial. Lancet Oncol. 2016; 17(6):757e67.

Lee DY, Huynh KT, Teng A, Lau BJ, Vitug S, Lee JH, et al. Predictors and survival impact of false-negative sentinel nodes in melanoma. Ann Surg Oncol. 2016; 23(3):1012-8. PMid:26586498 PMCid:PMC4984404

Wong SL, Faries MB, Kennedy EB, Agarwala SS, Akhurst TJ, Ariyan C, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018; 36(4):399-413. PMid:29232171

Bartlett EK, Peters MG, Blair A, Etherington MS, Elder DE, Xu XG, et al. Identification of patients with intermediate thickness melanoma at low risk for sentinel lymph node positivity. Ann Surg Oncol. 2016; 23(1):250-6. PMid:26215202 PMCid:PMC4697873

Han D, Zager JS, Shyr Y, Chen H, Berry LD, Iyengar S, et al. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol. 2013; 31(35):4387-93. PMid:24190111

Forschner A, Olthof SC, Guckel B, Martus P, Vach W, la Fougere C, et al. Impact of (18)F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. Eur J Nucl Med Mol Imaging. 2017; 44(8):1312-8. PMid:28315947

Fioranelli M, Roccia MG, Pastore C, Aracena CJ, Lotti T. Completion dissection or observation for sentinel-node metastasis in melanoma. Dermatol Ther. 2017; 30(6). PMid:28836714

Delgado AF, Delgado AF. Complete lymph node dissection in melanoma: a systematic review and meta-analysis. Anticancer Res. 2017; 37(12):6825-9.

Moody JA, Botham SJ, Dahill KE, Wallace DL, Hardwicke JT. Complications following completion lymphadenectomy versus therapeutic lymphadenectomy for melanoma - a systematic review of the literature. Eur J Surg Oncol. 2017; 43(9):1760-7. PMid:28756017

de Vries M, Hoekstra HJ, Hoekstra-Weebers JE. Quality of life after axillary or groin sentinel lymph node biopsy, with or without completion lymph node dissection, in patients with cutaneous melanoma. Ann Surg Oncol. 2009; 16(10):2840-7. PMid:19639366 PMCid:PMC2749179

How to Cite
Scala J, Vojvodic A, Vojvodic P, Vlaskovic-Jovicevic T, Peric-Hajzler Z, Matovic D, Dimitrijevic S, Vojvodic J, Sijan G, Stepic N, Wollina U, Tirant M, Nguyen VT, Fioranelli M, Lotti T. New Trends in Cutaneous Melanoma Surgery. Open Access Maced J Med Sci [Internet]. 2019Sep.14 [cited 2020Oct.20];7(18):3090-2. Available from:

Most read articles by the same author(s)

1 2 3 > >>